[go: up one dir, main page]

AR127141A1 - Método para producir células t - Google Patents

Método para producir células t

Info

Publication number
AR127141A1
AR127141A1 ARP220102574A ARP220102574A AR127141A1 AR 127141 A1 AR127141 A1 AR 127141A1 AR P220102574 A ARP220102574 A AR P220102574A AR P220102574 A ARP220102574 A AR P220102574A AR 127141 A1 AR127141 A1 AR 127141A1
Authority
AR
Argentina
Prior art keywords
cells
regulatory
expression construct
foxp3
cns3
Prior art date
Application number
ARP220102574A
Other languages
English (en)
Inventor
Shin Kaneko
Shoichi Iriguchi
Yoshiaki Kassai
Keiko Sekiya
Atsushi Matsuda
Takayuki Sato
Original Assignee
Univ Kyoto
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyoto, Takeda Pharmaceuticals Co filed Critical Univ Kyoto
Publication of AR127141A1 publication Critical patent/AR127141A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

Se divulga un método para producir células T reguladoras que comprende la siguiente etapa: (1) Diferenciar células que se pueden diferenciar en células T reguladoras, a las que se introduce un constructo de expresión, en células T reguladoras; el constructo de expresión comprende: (a) Secuencia no codificante conservada (CNS) 1, CNS2, y CNS3 del gen Foxp3; (b) Un promotor; y (c) Un ácido nucleico que codifica FOXP3. También se divulgan células T reguladoras obtenidas según el método, y una composición farmacéutica que comprende las células T reguladoras. Reivindicación 11: Células iPS a las que se introduce un constructo de expresión; el constructo de expresión comprende: (a) CNS1, CNS2, y CNS3 del gen Foxp3; (b) Un promotor; y (c) Un ácido nucleico que codifica FOXP3. Reivindicación 16: Un método para prevenir y/o tratar una respuesta inmune mejorada anormalmente, que comprende la administración de las células T reguladoras según la Reivindicación 13 a un sujeto que las necesite.
ARP220102574A 2021-09-27 2022-09-26 Método para producir células t AR127141A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2021157187 2021-09-27

Publications (1)

Publication Number Publication Date
AR127141A1 true AR127141A1 (es) 2023-12-20

Family

ID=85720842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102574A AR127141A1 (es) 2021-09-27 2022-09-26 Método para producir células t

Country Status (12)

Country Link
US (1) US20240400993A1 (es)
EP (1) EP4410965A4 (es)
JP (1) JPWO2023048275A1 (es)
KR (1) KR20240067089A (es)
CN (1) CN118056007A (es)
AR (1) AR127141A1 (es)
AU (1) AU2022349176A1 (es)
CA (1) CA3234008A1 (es)
CO (1) CO2024004812A2 (es)
MX (1) MX2024003619A (es)
TW (1) TW202330910A (es)
WO (1) WO2023048275A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250134927A1 (en) * 2021-09-08 2025-05-01 Orchard Therapeutics (Europe) Limited Compositions and methods for treating or preventing autoimmune diseases
CN119256076A (zh) * 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法
CN120112629A (zh) * 2022-09-26 2025-06-06 国立大学法人京都大学 T细胞产生方法
CN116640728B (zh) * 2023-07-24 2023-10-20 呈诺再生医学科技(北京)有限公司 RO8191和AS2863619在诱导产生表达成人型β珠蛋白的脱核红细胞中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE334609T1 (de) 2004-04-10 2006-08-15 Henkel Kgaa Lockenwickler
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP4223769A3 (en) 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
US7661738B2 (en) 2006-11-28 2010-02-16 Veritainer Corporation Radiation detection unit for mounting a radiation sensor to a container crane
EP3878949B1 (en) 2007-04-07 2025-06-04 Whitehead Institute for Biomedical Research Reprogramming of somatic cells
CN101802172A (zh) 2007-05-30 2010-08-11 通用医疗公司 由体细胞产生多能细胞的方法
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
JP2009237558A (ja) 2008-03-05 2009-10-15 Semiconductor Energy Lab Co Ltd 半導体装置の駆動方法
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
GEP201706771B (en) 2011-09-13 2017-11-27 TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
GEP201706688B (en) 2012-02-02 2017-06-26 Senex Biotechnology Inc Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer
HK1206741A1 (en) 2012-08-23 2016-01-15 霍夫曼-拉罗奇有限公司 Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
WO2014063778A1 (en) 2012-10-08 2014-05-01 Merck Patent Gmbh 2-aminopyridine compounds
GB201220157D0 (en) 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
KR20150092279A (ko) 2012-12-10 2015-08-12 에프. 호프만-라 로슈 아게 암의 치료를 위한 신규한 2-고리 페닐-피리딘/피라진
WO2014106606A1 (en) 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
WO2014154723A1 (en) 2013-03-29 2014-10-02 F. Hoffmann-La Roche Ag Novel pyrrole derivatives for the treatment of cancer
WO2014180943A1 (en) * 2013-05-08 2014-11-13 Vib Vzw Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders
WO2014194201A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
AR097894A1 (es) 2013-10-03 2016-04-20 Hoffmann La Roche Inhibidores terapéuticos de cdk8 o uso de los mismos
KR20160101162A (ko) 2013-12-24 2016-08-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유사체 및 그의 합성 및 용도
US9926319B2 (en) 2014-03-27 2018-03-27 Merck Patent Gmbh Pyridyl piperidines
WO2015159938A1 (ja) 2014-04-18 2015-10-22 武田薬品工業株式会社 複素環化合物
JP6521387B2 (ja) 2014-04-18 2019-05-29 武田薬品工業株式会社 縮合複素環化合物
US20160016951A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
IL258899B2 (en) * 2015-10-30 2024-03-01 Univ California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
JP7059481B2 (ja) 2016-06-23 2022-04-26 国立大学法人京都大学 Ｃｄ４ｃｄ８両陽性ｔ細胞の製造方法
JP6987338B2 (ja) * 2016-08-05 2021-12-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＭＨＣＩＩ拘束性ＣＤ４＋ＦＯＸＰ３＋制御性Ｔ細胞のｅｘ ｖｉｖｏ生成及びその治療的使用
EP4053268B1 (en) 2017-01-20 2025-10-08 Kyoto University Method for producing cd8alpha+beta+cytotoxic t cells
WO2018159805A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 膵前駆細胞の製造方法
EP4302768A3 (en) * 2017-06-22 2024-05-01 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
US12060566B2 (en) * 2017-08-22 2024-08-13 The Regents Of The University Of California Self-inactivating lentiviral vector comprising a FOXP3 expression cassette
US12077774B2 (en) * 2018-04-18 2024-09-03 UCL Business Ltd. Method for enhancing the suppressive properties of Treg cells
CN119709615A (zh) 2018-08-10 2025-03-28 国立大学法人京都大学 Cd3阳性细胞的制造方法
US20210238551A1 (en) * 2018-08-22 2021-08-05 Osaka University Method for Generating Regulatory T Cells
AU2020378228A1 (en) 2019-11-08 2022-05-26 Sangamo Therapeutics, Inc. Generation of engineered regulatory T cells
US20250195655A1 (en) * 2022-02-04 2025-06-19 Kyoto University T cell production method
CN119256076A (zh) * 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法

Also Published As

Publication number Publication date
EP4410965A1 (en) 2024-08-07
CA3234008A1 (en) 2023-03-30
MX2024003619A (es) 2024-04-19
CO2024004812A2 (es) 2024-05-20
CN118056007A (zh) 2024-05-17
EP4410965A4 (en) 2025-09-24
JPWO2023048275A1 (es) 2023-03-30
TW202330910A (zh) 2023-08-01
KR20240067089A (ko) 2024-05-16
WO2023048275A1 (ja) 2023-03-30
US20240400993A1 (en) 2024-12-05
AU2022349176A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
AR127141A1 (es) Método para producir células t
PH12022552687A1 (en) Method and drug for treating hurler syndrome
MX2022009836A (es) Vacuna para sars-cov-2.
BR112017017810A2 (pt) materiais e métodos para tratamento de hemoglobinopatias
MX2018011383A (es) Replicon de arn para la expresion genica versatil y eficiente.
BR112022003089A2 (pt) Métodos de produção de células progenitoras hemogênicas a partir de células-tronco pluripotentes
CO2021007372A2 (es) Ácidos nucleicos para inhibir la expresión de lpa en una célula
CY1120410T1 (el) Μεθοδος για την παραγωγη τοξινης αλλαντιασης
EA201001198A1 (ru) Рекомбинантные вирусоподобные частицы (вч), схожие с вирусом гриппа, производящиеся в трансгенных растениях, экспрессирующих гемагглютинин
EA201591043A1 (ru) Способ ферментации
UY36870A (es) Análogos de insulina novedosos
BR112022009836A2 (pt) Método para fornecer células imunes com função aumentada
MX2016009149A (es) Variantes mejoradas de enzimas.
BR112018005539A2 (pt) ?produção fúngica de fdca?
MX2021009554A (es) Produccion de virus en cultivos celulares.
MY198780A (en) Process for the biological production of methacrylic acid and derivatives thereof
CL2022003281A1 (es) Inducción de haploides en plantas.
ZA202304290B (en) Nucleic acid constructs, viral vectors and viral particles
PH12023550246A1 (en) Modified chikungunya viruses and sindbis viruses and uses thereof
DOP2024000204A (es) Composiciones y métodos para la prevención y el tratamiento de la infección por el virus de la rabia
MX2018015766A (es) Un proceso para producir cuero.
MX2023006445A (es) Composiciones y usos de estas para el tratamiento del síndrome de angelman.
AR113907A1 (es) Prolina hidroxilasas así como usos, métodos y productos que implican a las mismas
Kahn et al. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector‐based COVID‐19 vaccine: COMMENT from Gruel et al.: RESPONSE from Kahn et al.
EA201991083A1 (ru) Обработанный белковый продукт